A Short-term Preoperative, Window-of-opportunity Study, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer
Latest Information Update: 12 Dec 2025
At a glance
- Drugs Elacestrant (Primary) ; Leuprorelin (Primary)
- Indications Carcinoma; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms POP-ELA
Most Recent Events
- 01 Dec 2025 Planned End Date changed from 23 Mar 2027 to 29 May 2027.
- 01 Dec 2025 Planned primary completion date changed from 23 Nov 2026 to 29 Jan 2027.
- 01 Dec 2025 Status changed from not yet recruiting to recruiting.